October 31, 2023
Flare Therapeutics
Flare Therapeutics to Present New Translational Data in Support of Clinical Candidate FX-909’s Phase 1 Development at SITC 2023 Annual Meeting
October 31, 2023
Asher Bio
Asher Bio Presents Promising New Preclinical Data for Cis-targeted Cancer Immunotherapy AB821 at SITC Annual Meeting
October 31, 2023
Pliant Therapeutics
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society of Immunotherapy of Cancer
October 30, 2023
Rapport Therapeutics
Rapport Therapeutics Appoints Chief Financial Officer
October 19, 2023
Flare Therapeutics
Flare Therapeutics Announces First Patients Dosed in First-in-Human Phase 1 Clinical Study of FX-909 in Advanced Solid Malignancies, Including Urothelial Cancer